QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as
assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to
the SoC dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel (control
arm).